Pulse Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pulse Biosciences, Inc. on September 12, 2023, covering events occurring on September 10, 2023. The Company is a Delaware corporation with its principal executive offices in Hayward, California, and its common stock trades on The Nasdaq Stock Market under the symbol "PLSE".
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The report focuses exclusively on executive compensation arrangements.
Material Changes
On September 10, 2023, the Board of Directors approved one-time cash bonuses for two senior executives:
- Kevin Danahy (President and Chief Executive Officer): $300,000
- Darrin Uecker (Chief Technology Officer): $300,000
These bonuses were awarded for leadership and programmatic achievements in 2023. The parties agreed that these amounts will be credited against any future bonuses otherwise payable under the Company's 2023 bonus plan and their respective employment agreements.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of risks and contingencies beyond the specific compensation event.
Key Facts for Investor Verification
- Verify the total cash outflow of $600,000 for executive bonuses.
- Confirm the impact of these bonuses on the Company's 2023 bonus plan liabilities and future compensation obligations for the CEO and CTO.
- Review the Company's cash position to assess the liquidity impact of this immediate payout.